Vanguard Group
AERI

Vanguard Group’s Aerie Pharmaceuticals AERI Stock Holding History

Vanguard Group’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,441,120
Closed -$36.9M – 4594
2022
Q3 		$36.9M Sell
2,441,120
-278,367
-10% -$3.24M ﹤0.01% 2326
2022
Q2 		$20.4M Buy
2,719,487
+160,007
+6% +$1.13M ﹤0.01% 2630
2022
Q1 		$23.3M Sell
2,559,480
-821,888
-24% -$6.34M ﹤0.01% 2681
2021
Q4 		$23.7M Sell
3,381,368
-995,438
-23% -$10.4M ﹤0.01% 2749
2021
Q3 		$49.9M Buy
4,376,806
+27,124
+0.6% +$397K ﹤0.01% 2363
2021
Q2 		$69.6M Buy
4,349,682
+98,928
+2% +$1.7M ﹤0.01% 2193
2021
Q1 		$76M Buy
4,250,754
+33,683
+0.8% +$582K ﹤0.01% 2098
2020
Q4 		$57M Buy
4,217,071
+181,614
+5% +$2.19M ﹤0.01% 2129
2020
Q3 		$47.5M Sell
4,035,457
-224,251
-5% -$2.73M ﹤0.01% 2041
2020
Q2 		$62.9M Sell
4,259,708
-83,106
-2% -$1.23M ﹤0.01% 1887
2020
Q1 		$58.6M Buy
4,342,814
+105,323
+2% +$2M ﹤0.01% 1794
2019
Q4 		$102M Buy
4,237,491
+85,678
+2% +$1.77M ﹤0.01% 1740
2019
Q3 		$79.8M Sell
4,151,813
-36,633
-0.9% -$839K ﹤0.01% 1843
2019
Q2 		$124M Buy
4,188,446
+79,985
+2% +$3.08M ﹤0.01% 1633
2019
Q1 		$195M Buy
4,108,461
+72,024
+2% +$3.17M 0.01% 1359
2018
Q4 		$146M Buy
4,036,437
+148,857
+4% +$6.98M 0.01% 1450
2018
Q3 		$239M Buy
3,887,580
+436,964
+13% +$28.1M 0.01% 1259
2018
Q2 		$233M Buy
3,450,616
+247,966
+8% +$13.9M 0.01% 1253
2018
Q1 		$174M Buy
3,202,650
+146,507
+5% +$8.19M 0.01% 1378
2017
Q4 		$183M Buy
3,056,143
+54,704
+2% +$3.32M 0.01% 1362
2017
Q3 		$146M Buy
3,001,439
+842,614
+39% +$46M 0.01% 1480
2017
Q2 		$113M Buy
2,158,825
+766,300
+55% +$35.7M 0.01% 1602
2017
Q1 		$63.2M Buy
1,392,525
+92,463
+7% +$4.12M ﹤0.01% 1885
2016
Q4 		$49.2M Buy
1,300,062
+163,404
+14% +$6.18M ﹤0.01% 1986
2016
Q3 		$42.9M Buy
1,136,658
+130,106
+13% +$2.87M ﹤0.01% 2001
2016
Q2 		$17.7M Buy
1,006,552
+100,645
+11% +$1.63M ﹤0.01% 2381
2016
Q1 		$11M Buy
905,907
+52,351
+6% +$828K ﹤0.01% 2565
2015
Q4 		$20.8M Buy
853,556
+152,266
+22% +$3.55M ﹤0.01% 2291
2015
Q3 		$12.4M Buy
701,290
+122,131
+21% +$2.21M ﹤0.01% 2489
2015
Q2 		$10.2M Buy
579,159
+37,201
+7% +$682K ﹤0.01% 2660
2015
Q1 		$17M Buy
541,958
+214,725
+66% +$6.22M ﹤0.01% 2394
2014
Q4 		$9.55M Buy
327,233
+62,580
+24% +$1.59M ﹤0.01% 2559
2014
Q3 		$5.48M Buy
264,653
+71,248
+37% +$1.4M ﹤0.01% 2773
2014
Q2 		$4.79M Buy
193,405
+29,922
+18% +$518K ﹤0.01% 2853
2014
Q1 		$3.46M Buy
163,483
+71,383
+78% +$1.44M ﹤0.01% 2996
2013
Q4 		$1.65M Buy
+92,100
New +$1.2M ﹤0.01% 3264

Vanguard Group's AERI Position: Q4 2022 in Review

Vanguard Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 2,441,120 shares — an estimated $36.9M sold.

Vanguard Group first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $239M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Vanguard Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 2,441,120 Aerie Pharmaceuticals shares in Q4 2022, an estimated $36.9M.
  • Vanguard Group first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
  • Vanguard Group's Aerie Pharmaceuticals position peaked at $239M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.